Parexel, Medidata extend decentralized clinical trial partnership

By Jenni Spinner contact

- Last updated on GMT

(Tom Merton/iStock via Getty Images Plus)
(Tom Merton/iStock via Getty Images Plus)

Related tags: Parexel, Medidata, Decentralized trials, Virtual clinical trials, CRO, Contract research organization

The two companies, which have been collaborating for 15 years, reportedly will focus on elevating decentralized trial solutions to develop new therapies.

Medidata, a Dassault Systèmes company, has announced that it and clinical research organization (CRO) Parexel are extending their strategic partnership, which has gone on for 15 years prior to now. The collaboration will work toward “pioneering a new era of decentralized clinical trial technology.”

Additionally, Parexel participates in Medidata’s Early Adopter DCT program, which leverages the myMedidata patient portal, Sensor Cloud, and Medidata’s proprietary Patient Centricity by Design program; Parexel, in turn, provides feedback and insights to help ensure the portal meets the needs of patients, sites, and sponsors. myMedidata enables study patients to access their trial needs virtually via a web-based portal.

To learn more about the history and future of the collaboration between the two companies, Outsourcing-Pharma connected with two executives:

  • Anthony Costello, patient cloud CEO with Medidata
  • Clare Grace, chief patient officer at Parexel

OSP: Could you please share how Parexel and Medidata came to work together, and why the partnership has worked so well for so long?

AC: Our relationship with Parexel has been growing and developing for more than a decade now. As a world-leading CRO, Parexel was seeking partners that had state-of-the-art systems to collect data from clinical trials in an efficient, regulatory-approved manner that would easily meet all patient safety and privacy requirements.

While Parexel’s relationship with Medidata was born through the use of electronic data capture (EDC); we have continued to strengthen our partnership through more patient-centric solutions that continue to enhance Parexel’s services delivering better clinical trials for sponsors and patients.

OSP: Do you have any notable achievements born out of the long-running partnership that you’d like to brag about?

AC: In early February we announced an extension of our 15-year global strategic partnership to enhance the delivery of decentralized clinical trials. Parexel is also the largest CRO to be part of the Early Adopter Program for myMedidata, a web-based patient portal enabling decentralized clinical trials. Alternatively, another notable achievement is Parexel’s global use of Medidata’s Rave Site Payments solution to support all sites and investigator payments.

OSP: Both companies mention work about DCTs—could you please share any specific plans or goals the collaborators have about DCT development?

CG: Clare Grace: As Anthony mentioned earlier, Parexel is the largest CRO that participated in the myMedidata Early Adopter Program. The program enabled us to provide input into the development of the platform with the ability to offer direct feedback into the functionality, usability, and development of the patient engagement interface of the solution. Within this program, Parexel is also supporting testing and validation myMedidata for use in DCTs.

Over the long term, our partnership with Medidata is an opportunity to enhance our patient-first efforts in clinical trials, especially around DCT and hybrid studies.

Related news

Show more

Related products

show more

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Formedix | 20-Jun-2022 | Technical / White Paper

This article explains the different types of clinical trial software available, and how it can be used to optimize the end to end clinical trials design...

Strategic Approach to Immunogenicity Assessment

Strategic Approach to Immunogenicity Assessment

Altasciences | 17-May-2022 | Technical / White Paper

In this issue of The Altascientist we provide a detailed overview on the different goals and challenges that are presented by the validation of immunogenicity...

Governing and Maintaining Clinical Data Standards

Governing and Maintaining Clinical Data Standards

Veeva | 10-May-2022 | Technical / White Paper

Investing in data standards plays a huge role in improving the quality of clinical studies. But often, people don’t use the standards correctly, there...

What the Best Clinical Study Build Pros Do

What the Best Clinical Study Build Pros Do

Formedix | 09-May-2022 | Technical / White Paper

Getting your clinical study designed and built ready for data collection takes A LOT of work and expertise… you've got to do all your CRF designs;...

Related suppliers

Follow us


View more